Suppr超能文献

放射性标记去纤苷在大鼠口服或静脉给药后的药代动力学研究。

Study on pharmacokinetics of radioactive labelled defibrotide after oral or intravenous administration in rats.

作者信息

Fisher J, Holland T K, Pescador R, Porta R, Ferro L

机构信息

Inveresk Research International, Tranent, Scotland.

出版信息

Thromb Res. 1996 Jan 1;81(1):55-63. doi: 10.1016/0049-3848(95)00213-8.

Abstract

Defibrotide (D) was labelled with 125I or with 32P. The radiolabelled compounds ([125I]-Defibrotide ([125I]-D), [32P]-Defibrotide ([32P]-D) retained the same profibrinolytic activity, in vitro, as the parent drug, suggesting that the labelling procedures had not modified the pharmacological properties of D and hence that its chemical structure was not affected significantly. After single intravenous or oral administration of [125I]-D or [32P]-D the pharmacokinetic parameters for the two labels were generally in good agreement (75%). t 1/2 alpha was in the range of minutes while t 1/2 beta was in the range of hours. Bioavailability, following single oral administration of [125I]-D or [32P]-D, was in the range of 58-70%. These data suggest that D, in spite of its macromolecular nature, is absorbed, after oral administration, fairly well.

摘要

去纤苷(D)用125I或32P进行标记。放射性标记化合物([125I] - 去纤苷([125I] - D),[32P] - 去纤苷([32P] - D))在体外保留了与母体药物相同的促纤溶活性,这表明标记过程未改变D的药理特性,因此其化学结构未受到显著影响。单次静脉注射或口服[125I] - D或[32P] - D后,两种标记物的药代动力学参数总体上吻合良好(75%)。t 1/2α在数分钟范围内,而t 1/2β在数小时范围内。单次口服[125I] - D或[32P] - D后的生物利用度在58 - 70%范围内。这些数据表明,D尽管具有大分子性质,但口服后吸收相当良好。

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验